Institutional target prices can no longer keep up with Moderna's soaring stock price; can tomorrow's earnings report support a $100 billion market cap?

BlockBeats news, November 5th - Moderna's US stock surged 13.1% in the previous trading day, closing at $258.38, with an intraday high of $258.7, setting a new 52-week high and pushing its total market capitalization past $103 billion. The company is set to release its third-quarter earnings report before the US market opens on November 6th and will hold a conference call at 21:00 Beijing time that evening.

Furthermore, Moderna's stock price has risen much faster than most Wall Street analysts' valuation adjustments. According to statistics from Futu, based on data from 13 renowned analysts, the average target price for the next 12 months is approximately $142.22, with the highest at only $230. The current stock price of $258.38 is about 81.7% higher than the average target price and about 12.3% higher than the highest target price. Using a larger sample of 23 analysts covered by S&P Global, the average target price is only $138.37, with the highest at $251, also below the current stock price. However, Wall Street's consensus rating for Moderna remains at "Hold."

From a financial fundamentals perspective, currently